Catalyst Pharma, Health Catalyst Post Divergent Q2 Results

Health Catalyst (HCAT) reported adjusted Q2 2025 earnings of $0.04 per share, beating the Zacks Consensus Estimate but down from $0.12 last year, with revenues rising to $80.72 million. Despite surpassing earnings expectations, Health Catalyst shares have declined about 46% year-to-date, underperforming the S&P 500, as investors focus on future outlook and estimate revisions. Catalyst Pharmaceuticals (CPRX) posted adjusted Q2 earnings of $0.68 per share, exceeding estimates and last year's figure, with revenues up 19% year over year to $146.6 million, driven by strong sales of Firdapse and newly acquired or launched drugs, though Fycompa revenues fell due to generic competition. Both companies experienced stock volatility, with Health Catalyst's decline being steeper. Analysts maintain a positive outlook on Catalyst Pharmaceuticals, citing strong financials and product demand. The differing stock performances of the two companies reflect varying market pressures and competitive environments.